Sofalcone, a mucoprotective drug, inhibits platelet activation and arterial thrombosis.
Abstract
Gastrointestinal injury remains a major limitation of aspirin-based antiplatelet therapy. Sofalcone is a clinically used mucoprotective drug with an established safety profile, but its effects on platelet function remain unclear. This study aims to evaluate the antiplatelet effects of sofalcone and elucidate its underlying mechanisms. In human platelets, sofalcone inhibited platelet adhesion on collagen and suppressed aggregation and secretion induced by U46619, collagen, and arachidonic acid. It converted ADP-induced irreversible aggregation into a reversible response while minimally affecting thrombin-induced aggregation or coagulation parameters. Sofalcone did not alter TXA2 production or activate cyclic AMP or cyclic GMP signaling. Instead, it produced rightward shifts in U46619 concentration-response curves and attenuated TP receptor-mediated Ca2+ mobilization in platelets and TP-expressing HEK293T cells. Docking analysis suggested interaction with the TP receptor binding pocket. Notably, a long half-life major metabolite of sofalcone displayed slightly greater antiplatelet potency. Under whole blood flow conditions, sofalcone and its metabolite reduced thrombus formation on collagen-coated microfluidic chamber surfaces. Combination treatment with sofalcone and either aspirin or ticagrelor further enhanced the inhibition of platelet aggregation and thrombus formation. In mice, intraperitoneal or oral sofalcone prevented FeCl3-induced arterial thrombosis without prolonging tail bleeding time. Together, these findings support the potential repurposing of sofalcone as an alternative or adjunctive antiplatelet therapy, particularly in settings where gastrointestinal protection is clinically desirable.